Guardant Health Stock Forecast, Price & News

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GH stock has increased by 96.4% and is now trading at $123.65.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Guardant Health or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Guardant Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Guardant Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Guardant Health is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Guardant Health.

Guardant Health, Inc. (NASDAQ:GH) posted its quarterly earnings results on Thursday, November, 5th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.44. The firm earned $74.66 million during the quarter, compared to the consensus estimate of $65.99 million. Guardant Health had a negative return on equity of 19.22% and a negative net margin of 67.14%. The company's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.14) earnings per share.
View Guardant Health's earnings history.

8 Wall Street analysts have issued twelve-month price objectives for Guardant Health's shares. Their forecasts range from $100.00 to $135.00. On average, they expect Guardant Health's stock price to reach $119.00 in the next twelve months. This suggests that the stock has a possible downside of 3.8%.
View analysts' price targets for Guardant Health.

Some companies that are related to Guardant Health include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), Elekta AB (publ) (EKTAY), Veracyte (VCYT), CareDx (CDNA), Burning Rock Biotech (BNR), Genetron (GTH), Personalis (PSNL), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), RadNet (RDNT), Renalytix AI (RNLX) and DermTech (DMTK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), The Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Guardant Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (6.31%), BlackRock Inc. (5.01%), Jennison Associates LLC (3.20%), Nuveen Asset Management LLC (2.88%), Massachusetts Financial Services Co. MA (1.08%) and Allianz Asset Management GmbH (0.95%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends for Guardant Health.

GH stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, ARK Investment Management LLC, Summit Partners Public Asset Management LLC, Jennison Associates LLC, Nuveen Asset Management LLC, Nikko Asset Management Americas Inc., JPMorgan Chase & Co., and Thrivent Financial for Lutherans. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health.

GH stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Point72 Asset Management L.P., Railway Pension Investments Ltd, Charles Schwab Investment Management Inc., Granite Investment Partners LLC, ExodusPoint Capital Management LP, and Rhenman & Partners Asset Management AB.
View insider buying and selling activity for Guardant Health.

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GH stock can currently be purchased for approximately $123.65.

Guardant Health has a market capitalization of $12.36 billion and generates $214.38 million in revenue each year. The company earns $-75,650,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Guardant Health employs 622 workers across the globe.

The official website for Guardant Health is www.guardanthealth.com.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.